Manuel Silva

Manuel Silva has extensive work experience in the field of clinical biomarkers and companion diagnostics. Manuel currently holds the position of Principal Clinical Biomarker Lead - Oncology at Boehringer Ingelheim since 2021. Prior to this, they worked at Merck Group as the Clinical Biomarkers & Companion Diagnostics Lead and later as the Director Integrative & Experimental Pathology, Global Clinical Biomarkers & Companion Diagnostics. At Merck, they were involved in developing and implementing biomarker strategies for immuno-oncology projects and clinical programs for various solid tumor indications. Manuel also played a role in due diligence assessments for immuno-oncology drug candidates and led the expansion of a human tumor tissue bank. Before their time at Merck, Manuel worked at Roche Diagnostics as the Lab Head Non-Clinical Safety & Investigative Pathology, Oncology, pRED, providing tissue-based biomarker solutions for drug development. Manuel has also held positions at McMaster University and Novartis Horsham Research Centre as a post-doctoral research fellow and Head of Histopathology and Investigator II, respectively. Manuel's research experience includes investigating viral modulation of colonic cytokines and the role of IL-15 in Crohn's disease. Overall, Manuel Silva has a diverse professional background in the field of clinical biomarkers and has made significant contributions to the development and implementation of biomarker strategies in immuno-oncology.

Manuel Silva completed their education at the Pontificia Universidad Católica de Chile. From 1989 to 1996, they obtained a professional title equivalent to a Master's degree in Biochemistry. Following that, they pursued General Medicine & Clinical Internship, earning an M.D. degree from 1994 to 1999.